This result is in line with findings from studies in small-cell lung and triple-negative breast cancers, where CPS by integrating PD-L1 expression on both tumor and immune cells captures a broader spectrum of PD-L1 positivity [15,59]. This evidence concerns the gene CD274 and triple-negative breast carcinoma.